Advantages and risks of the use of prostate specific antigen (PSA) in the sanitary area V of Gijón (Asturias);Ventajas y riesgos de la utilización del antígeno prostático específico (PSA) en el área sanitaria v de gijón (Asturias)

Archivos Espanoles de Urologia

Volumn 58, Issue 5, 2005, Pages 403-411

  Cepeda Piorno, Javier ^a   Rivas Del Fresno, Manuel ^a   Fuente Martín, Eduardo ^a   González García, Esther ^a   Muruamendiaraz Fernández, Valentín ^a   Fernández Rodríguez, Eloy ^a  

^a HOSPITAL DE CABUEÑES   (Spain)

Author keywords

Prostate cancer; PSA; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BIOPSY; BLOOD; EARLY DIAGNOSIS; EVALUATION; HUMAN; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PATHOLOGY; PATIENT REFERRAL; PREDICTION AND FORECASTING; PRIMARY HEALTH CARE; PROSTATE; PROSTATE TUMOR; RETROSPECTIVE STUDY; RISK; SENSITIVITY AND SPECIFICITY; SPAIN; STATISTICS; UROLOGY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; EARLY DIAGNOSIS; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; RISK; SENSITIVITY AND SPECIFICITY; SPAIN; TUMOR MARKERS, BIOLOGICAL; UROLOGY;

EID: 27144485782     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. WESTRA, C.S.; DUCATMAN, A.M.; NIEWIADOMSKA-BUGAJ, M. y cols.: "An Estimate of prostate cancer prevalence for a demographically similar workforce population". W. V. Med. J., 95: 116, 1999.
2. JOAN AREAL CALAMA: "Biopsia prostática ¿Cuándo y cómo debe plantearse?" Hospital Practice, 4: 53, 2002.
3. SCHERSTEN, T.; BAIH, M.A.; ASUA, J. y cols.: "Prostate cancer screening. Evidence synthesis and update. Statement of findings". INHATA joint projet. Vitoria-Gasteiz: Office of Health Technology Assesment (Osteba). Department of Health Basque Government. 1999.
4. NEAL, D.; DONNOVAN, J.: "Prostate Cancer: to screen or not to screen ?" Lancet Oncol, 1: 17, 2000.
5. SMITH, P.G.: "Comparison between registries: age-standardized rates". Parkin D H; Muir C.S; Whelan S.L; Gao Y.T; Ferlay J; Powell J. Cancer incidence in five continents. Vol VI. IARC. Scientific Publications N° 120; Lyon, 1992.
6. Atlas de incidencia de Cáncer en Asturias 1982-1993: mapas municipales y evolución temporal. Consejería de Salud y Servicios Sanitarios y Servicio de publicaciones del Principado de Asturias.
7. BARRY, M.J.: "Prostate-specific-antigen testing for early diagnosis of prostate cancer". N. Engl. J. Med., 344: 1373, 2001.
8. CARTER, H.B.; PEARSON, J.D.; METTER, E.J. y cols.: "Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease". JAMA, 267: 2215, 1992.
9. FOWLER, F.J.; McNAUGHTON COLLINS, M.; ALBERTSEN, P. y cols.: "Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer". JAMA, 283: 3217, 2000.
10. BABAS, S.: "Epidemiology of cancer of the prostate. Analysis of Countries of high and low incidence in prostate cancer". GH Jacobi; R Hohenfellner, cap.2, Williams and Wilkins, Baltimore; 1982.
11. U.S. Preventive Services Task Force, 1999. http://www..Ahcpr.gov.
12. ALONSO, J.M.; BELLAS, B.; CIERCO, P. y cols.: "Prevencion del cancer". Atencion Primaria, 24 (supl.1): 76, 1999.
13. The NHS Prostate Cancer Programme. http://www.Doh.gov.uk/cancer/pdfs/ prostate.pdf.
14. MOLD, J.W.; HOLTGRAVE, O.K.; KISONNI, K.S. y cols.: "The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis". J. Fam. Pract., 34: 561, 1992.
15. KRAHN, M.D.; MAHONEY, J.E.; ECKMAN, M.H. y cols.: "Screening for prostate cancer. A decision analytic view". JAMA, 272: 773, 1994.
16. FLEMING, C.; WASSON, J.H.; ALBERTSEN, P.C. y cols.: "A decision analysis of alternative treatment strategies for clinically localized prostate cancer". JAMA, 269: 2650, 1993.
17. ROERHBAN, G.G.; PREKENS, C.J.; CARNADY, T.: "Variability of repeated serum PSA measurements within less than 90 days in a well defined patient population". Urology, 47: 59, 1996.
18. DEJTER, S.W.; MARTIN, J.S.; McPHERSON, R.A. y cols.: "Daily variability in human serum prostate-specific antigen and prostatic acid phosphatase: A comparative evaluation". Urology, 32: 288, 1988.
19. MAATMAN, T.J.: "The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate". J. Urol., 141: 1378, 1989.
20. RANA, B.; CHSIHOLM, G.B.: "He sold his bike for a low prostate-specific antigen". J. Urol., 151: 700, 1994.
21. OESTERLING, J.E.; JACOBSEN, S.J.; CHUTE, G.G. y cols.: "Serum prostate-specific antigen in a community-based population healthy men: establishment of age-specific reference ranges". JAMA, 270: 860, 1993.
22. PARTIN, A.W.; CRILEY, S.R.; SUBONG, E.N.P. y cols.: "Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: a pathological analysis". J. Urol., 155: 1336, 1996.